On-demand video:

EULAR Highlights

from the virtual EULAR meeting 2020

EULAR 2020 summarized by professors Paul Emery (U.k.) and Tore Kvien (Norway)

In our two videos below, professors Paul Emery (U.K.) and Tore Kvien (Norway) summarize the most important highlights from the virtual EULAR congress 2020. Please note that these videos are intended for Healthcare professionals only.

EULAR Highlights video - Part 1 (Rheumatoid Arthritis and Prevention)

EULAR Highlights video - Part 2 (PsA, Spondyloarthritis, SLE, and others)

About the Speakers

Paul Emery

AR UK Professor of Rheumatology in Leeds since 1995 and Director of the Leeds NIHR Biomedical Research Centre since 2009.

Former President of EULAR.

Tore Kvien

Professor of Rheumatology at the University of Oslo since 1997 and Head of the Department of Rheumatology at Diakonhjemmet Hospital, Oslo, Norway since 1994.

AN INDEPENDENT REVIEW

These educational videos was created by the independent medical educations- and publishing company Mediahuset, sponsored by Gilead Sciences, and intended for healthcare providers only. The content was solely decided by the speakers - not Mediahuset, nor Gilead, was able to influence the content.

Disclaimer

  • Please note that Gilead does not recommend the use of any product in any different manner than as described in the Local Prescribing Information.
  • All opinions represented in this lecture are entirely the speaker’s views and do not necessarily represent Gilead.
  • If you have any questions related to Gilead products please send them to: askgileadME@gilead.com

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions via the national reporting schemes as applicable Adverse reactions may also be reported directly to the manufacturer of the suspected product. Adverse reactions related to Gilead products may be reported directly to Gilead via Drugsafety.dubai@gilead.com

These videos was sponsored by Gilead Sciences.